Search Results

You are looking at 41 - 50 of 403 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Cervical Cancer, Version 2.2015

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

single agents in the metastatic disease setting based on several randomized phase III trials. 18 , 19 Cisplatin is a standard backbone of combination chemotherapy regimens, and cisplatin-based chemotherapy regimens (eg, cisplatin/paclitaxel/bevacizumab

Full access

Next-Generation Cancer Vaccine Approaches: Integrating Lessons Learned From Current Successes With Promising Biotechnologic Advances

Dung T. Le and Elizabeth M. Jaffee

antigen-specific T cells and other agents to block T-cell inhibitory signals. Commercial grade agents are available or will become available to test in combinations. Examples include: 1) bevacizumab; 2) celecoxib; 3) GCS-100; 4) GC-1008; 5

Full access

Treatment of Locally Advanced/Metastatic Colorectal Cancer

Presented by: Alan P. Venook and Christopher G. Willett

“The introduction of FOLFOX and bevacizumab in the early 2000s raised our hopes that progress would be rapid and definitive. Although patients with advanced disease now live longer than in the past—many for ≥3 years—progress has largely stalled

Full access

Management of Central Nervous System Tumors

Thomas Kaley and Louis B. Nabors

-refractory meningiomas represents an unmet clinical need. There are no FDA-approved therapies. The NCCN Guidelines suggest sunitinib, interferon alfa, or bevacizumab plus everolimus as category B recommendations.” RANO Review “This review was based on 43 publications on

Full access

Systemic Therapy Options for Peritoneal Mesothelioma

Tawee Tanvetyanon and George R. Simon

. Cisplatin Pemetrexed and Bevacizumab In a phase III study conducted by the French Cooperative Thoracic Intergroup, patients with unresectable pleural mesothelioma with no cardiovascular comorbidity and not taking anticoagulation or antiplatelet medications

Full access

Antiangiogenesis Treatment for Glioblastoma Multiforme: Challenges and Opportunities

Eric T. Wong and Steven Brem

: 347 – 356 . 2. Folkman J . Tumor angiogenesis: therapeutic implications . N Engl J Med 1971 ; 285 : 1182 – 1186 . 3. Willett CG Boucher Y di Tomaso E . Direct evidence that the VEGF-specific antibody bevacizumab has

Full access

Updates in the Treatment of Metastatic Colorectal Cancer

Presented by: Midhun Malla, Katrina S. Pedersen, and Aparna R. Parikh

metastatic CRC space, the combination of trifluridine/tipiracil + bevacizumab has emerged as a potential new standard of care based on findings from the SUNLIGHT study. This open-label, randomized phase III trial enrolled patients with refractory metastatic

Full access

Access to and Appropriateness of Cancer Care: Who Decides?

William T. McGivney

Recent decisions about the optimal frequency and population age for screening mammography and the appropriate uses of bevacizumab and sipuleucel-t have raised questions, if not concerns, about both the decision-making processes and the level of

Full access

Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab

Emil Lou, Donna D'Souza, and Andrew C. Nelson

carcinoembryonic antigen (CEA) biomarker while on combination chemotherapy (FOLFIRI with bevacizumab), bevacizumab was discontinued in favor of initiating an EGFR inhibitor (panitumumab) while continuing the FOLFIRI backbone. This alteration to her treatment

Full access

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson, Michael I. D’Angelica, Daniel E. Abbott, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, Mitesh Borad, Daniel Brown, Adam Burgoyne, Prabhleen Chahal, Daniel T. Chang, Jordan Cloyd, Anne M. Covey, Evan S. Glazer, Lipika Goyal, William G. Hawkins, Renuka Iyer, Rojymon Jacob, R. Kate Kelley, Robin Kim, Matthew Levine, Manisha Palta, James O. Park, Steven Raman, Sanjay Reddy, Vaibhav Sahai, Tracey Schefter, Gagandeep Singh, Stacey Stein, Jean-Nicolas Vauthey, Alan P. Venook, Adam Yopp, Nicole R. McMillian, Cindy Hochstetler, and Susan D. Darlow

against lenvatinib alone for the frontline treatment of unresectable or metastatic HCC ( ClinicalTrials.gov identifier: NCT03713593). Atezolizumab and Bevacizumab Bevacizumab, a VEGF inhibitor, has modest clinical activity as a single agent or in